PARSIPPANY, N.J. & TEL AVIV & PARIS, May 08, 2024--ACCESS HERE THE COMPLETE PRESS RELEASE
MONTPELLIER, France, May 08, 2024--Regulatory News: The listing of the Medincell (Paris:MEDCL) shares on Euronext Paris has been suspended at the request of the Company, pending the publication of a press release. Trading on Euronext Paris will resume tomorrow at the opening of markets.
MONTPELLIER, France, April 16, 2024--Medincell (Paris:MEDCL) today announced a collaboration with AbbVie to co-develop and commercialize up to six therapeutic products across multiple therapeutic areas and indications. Medincell will use its commercial-stage long-acting injectable technology platform to formulate innovative therapies. Medincell will conduct formulation activities and preclinical studies, including supportive CMC work to advance candidates into clinical trials. AbbVie will financ